압타머 시장 규모, 점유율, 동향 및 예측 : 종류별, 용도별, 지역별(2026-2034년)

The global aptamers market size was valued at USD 3.6 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 14.4 Billion by 2034, exhibiting a CAGR of 16.26% during 2026-2034. North America currently dominates the market, holding a significant market share of 40.7% in 2025. The market is driven by advancements in biotechnology, increasing applications in diagnostics and therapeutics, and growing demand for personalized medicine. Their advantages, including high stability, specificity, and cost-effectiveness, make them ideal for a range of medical uses, thereby expanding the aptamers market share.

The aptamers market is driven by advancements in biotechnology, which have enabled the development of more efficient and stable aptamers, enhancing their use in diagnostics and therapeutics. Increased demand for personalized medicine has spurred the need for highly specific and targeted diagnostics, where aptamers excel due to their binding affinity and versatility. Cost-effectiveness and ease of synthesis make aptamers an attractive alternative to antibodies, offering significant savings in research and production. Regulatory support and funding for research in various regions facilitate the approval and commercialization of aptamer-based products. The growing applications in drug discovery, disease detection, and targeted therapies further fuel the expansion of the aptamers market, establishing them as a key tool in modern healthcare.

The aptamers market growth in the United States is driven by advancements in biotechnology have led to improved aptamer selection and stability, expanding their applications in diagnostics and therapeutics. Regulatory support facilitates the commercialization of aptamers, encouraging innovation. The rising demand for personalized medicine increases the need for efficient and precise diagnostic tools. Furthermore, substantial investments in research and development from both the public and private sectors accelerate the adoption of aptamers in healthcare. For instance, in October 2023, Zentek Ltd., a firm that develops and commercializes intellectual property technologies, announced the establishment of a wholly-owned subsidiary that will have the exclusive worldwide license rights for all aptamer-based technology developed in partnership with McMaster University. The rapid-detection platform and the new aptamer-based platform technology created by Dr. Yingfu Li and his team are included in this licensing deal. Preclinical research being carried out by Dr. Matthew Miller and his team indicates that this technology has potential as a treatment. The purpose of this new organization is to disseminate the aptamer technology to prospective biotech investors, foster cooperation and licensing agreements with the pharmaceutical industry, and expedite the development of the technology.

APTAMERS MARKET TRENDS:

Advancements in Biotechnology

The continuous advancements in biotechnology have significantly contributed to the growth of the aptamers market. Researchers are improving aptamer selection methods, enhancing their specificity and stability. With advancements in high-throughput screening techniques and chemical modifications, aptamers are becoming more versatile and effective for a wide range of applications. The ability to engineer aptamers for precise binding to target molecules has made them highly useful in diagnostics, therapeutic development, and disease monitoring. These innovations are enabling aptamers to compete with traditional antibodies in terms of performance, which is increasing their adoption in various healthcare sectors, fueling the aptamers market share. For instance, in November 2024, Aptamer Group revealed that a client in genetic medicines has opted to advance to the last stage of commercial development for Optimer delivery vehicles. The performance of these delivery vehicles has been confirmed by the customer, showing that the Optimer delivery vehicles can specifically aim at the desired cell type, with the possibility of being utilized in a precision therapy.

Rising Demand for Personalized Medicine

The growing focus on personalized medicine has become a significant driver for the aptamers market. Personalized medicine seeks to customize healthcare treatments for each patient according to their genetic profile, lifestyle choices, and disease traits. Aptamers, with their ability to precisely target specific biomarkers or molecules, align perfectly with the goals of personalized therapies. Their versatility makes them ideal for the development of diagnostic tests and targeted therapies, particularly in oncology, genetic disorders, and autoimmune diseases. As the demand for more accurate, individualized treatment options grows, the role of aptamers in personalized medicine continues to expand, creating a positive impact on the aptamers market outlook. For instance, in May 2024, Aptamer Group plc, the creator of innovative Optimer(R) binders aimed at advancing the life sciences sector, entered into an agreement with Timser Group, a pharmaceutical firm dedicated to women's health, with a contract worth up to £465,000.

Cost-Effectiveness and Versatility

Aptamers offer several advantages over traditional antibodies, particularly in terms of cost-effectiveness and ease of production. Unlike antibodies, aptamers can be synthetically produced in large quantities, eliminating the need for animal-derived materials and making them more affordable. Their production is highly scalable, which lowers overall manufacturing costs. Additionally, aptamers are stable under various conditions and have long shelf lives, reducing storage costs. These benefits make aptamers an attractive option for diagnostic and therapeutic applications, further driving their market adoption. According to the aptamers market forecast, their versatility, including use in biosensors, drug delivery systems, and molecular imaging, expands their potential, contributing to market growth. For instance, in April 2024, Aptamer Group, the creator of innovative Optimer binders designed to foster advancements in the life sciences sector, revealed the advancement of a collaboration with Kairos Biotech, an early-stage firm working on unique therapeutic solutions for transplant rejection.

APTAMERS INDUSTRY SEGMENTATION:

Analysis by Type:

• Nucleic Acid
• Peptide

Nucleic acid stand as the largest type in 2025, holding around 77.2% of the market. Nucleic acids hold the largest share in the aptamers market due to their superior stability, specificity, and ease of synthesis compared to other aptamer types. DNA and RNA aptamers offer a broad range of applications in diagnostics and therapeutics because they can be designed to target a wide variety of biomolecules with high precision. Their ability to be engineered for different conditions, along with their chemical stability and ease of mass production, makes them highly advantageous. Additionally, advancements in nucleic acid-based technologies have led to the increased use of DNA and RNA aptamers, further solidifying their dominance in the market.

Analysis by Application:

• Diagnostics
• Therapeutics
• Research and Developments
• Others

Diagnostics leads the market with around 36.8% of market share in 2025. Diagnostics holds the largest share in the aptamers market due to the high specificity, stability, and versatility of aptamers for detecting biomarkers. Unlike traditional antibodies, aptamers can be easily synthesized, modified, and used in a wide range of diagnostic applications, including disease detection and monitoring. Their ability to bind to specific targets with high affinity makes them ideal for both laboratory and point-of-care diagnostic tests. Furthermore, aptamers offer advantages like cost-effectiveness and faster development times, making them a popular choice for diagnostic applications in fields such as oncology, infectious diseases, and personalized medicine. This has significantly contributed to their dominance in the market.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 40.7%. The factors escalating the aptamers market demand in North America include advancements in biotechnology, which enhance the performance of aptamers in diagnostics and therapeutics. Regulatory support, particularly in the U.S., accelerates product approval and adoption. The rising demand for personalized medicine and precision diagnostics boosts the need for efficient tools like aptamers. Additionally, significant investment in research and development by both public and private sectors fosters innovation, further expanding the market. These elements collectively contribute to the robust growth of the aptamers market in North America.

KEY REGIONAL TAKEAWAYS:

UNITED STATES APTAMERS MARKET ANALYSIS

In 2025, the United States accounted for over 87.50% of the aptamers market in North America. The United States is witnessing a significant surge in aptamers demand, primarily driven by the rising prevalence of cardiovascular cases. As reported by the American Heart Association, cardiovascular disease (CVD) stands as the foremost cause of death in the United States, resulting in close to 2,500 deaths each day. Aptamers offer high specificity and stability, making them ideal for targeting cardiovascular biomarkers. With an increasing number of individuals diagnosed with heart-related conditions, the healthcare sector is embracing aptamer-based diagnostics and therapeutics as effective solutions. The biotechnology sector is increasingly investing in aptamer platforms to support precision medicine for cardiovascular care. Research institutions and companies are conducting advanced clinical trials focused on aptamer formulations for heart disease. Cardiovascular cases are pushing medical professionals to shift towards more reliable, targeted alternatives compared to traditional antibodies. As the burden of heart ailments rises, aptamers are emerging as a key component in diagnostic assays, molecular imaging, and therapeutic strategies tailored to cardiovascular management.

ASIA PACIFIC APTAMERS MARKET ANALYSIS

Asia-Pacific is experiencing increased aptamers usage influenced by the growing cases of acquired immunodeficiency syndrome (AIDS). For instance, in 2025, Mizoram exhibits the highest HIV prevalence rate in India, recorded at 2.73%, greatly exceeding the national average of 0.2%. The heightened demand stems from aptamers' strong potential to identify and bind to specific HIV-related proteins, improving diagnostic speed and accuracy. Healthcare providers are adopting aptamer-based tools to better manage AIDS progression, especially in resource-limited settings where affordability and stability of diagnostics are critical. Research in this region is centered on developing cost-effective, non-immunogenic aptamer solutions for viral detection. The biomedical community is increasingly focused on integrating aptamers into therapeutic pipelines for antiretroviral resistance studies. Rising AIDS incidence is fueling interest in alternative detection technologies that offer high sensitivity and easy customization. With growing awareness and research funding, aptamers are being positioned as a promising avenue for enhancing AIDS-related healthcare interventions across clinical and community settings.

EUROPE APTAMERS MARKET ANALYSIS

Europe is witnessing the rising aptamers deployment in response to its growing geriatric population. According to the WHO, the demographic of individuals aged 60 and above is swiftly increasing in the WHO European region. In 2021, the figure stood at 215 million; by 2030, it is expected to reach 247 million, and by 2050, it is expected to exceed 300 million. As age-related diseases such as neurodegenerative and chronic inflammatory conditions become more common, the healthcare system is turning to aptamers for early and precise diagnostics. Aptamers' small size and adaptability allow them to function effectively in complex aging biological systems. With an aging population needing personalized treatments, aptamer-based approaches offer less immunogenicity and better tissue penetration compared to antibodies. Biomedical developers are working on age-specific drug delivery systems using aptamers for conditions like Alzheimer's and arthritis. The increase in clinical trials involving older adults highlights the region's focus on customized therapeutic strategies. Geriatric population growth is influencing regulatory bodies and medical researchers to promote aptamer inclusion in diagnostic and therapeutic pathways. Enhanced healthcare investments are further accelerating this transition toward aptamer technologies.

LATIN AMERICA APTAMERS MARKET ANALYSIS

Latin America is observing growing aptamers integration in clinical practices due to increasing cancer cases. For instance, in 2025, cancer continues to be one of the primary causes of mortality in Latin America, taking the lives of over 1.4 million individuals and leading to more than 4 million new cases every year. Aptamers provide targeted delivery mechanisms and are being used for cancer detection and treatment monitoring. Their ability to bind specific tumor markers with high precision is enhancing oncological research and diagnostics. With cancer cases on the rise, demand for effective molecular tools like aptamers is steadily climbing, making them essential in new oncology protocols across the region.

MIDDLE EAST AND AFRICA APTAMERS MARKET ANALYSIS

The Middle East and Africa is showing increased interest in aptamers, supported by expanding healthcare facilities. A report by the Ministry of Economy anticipates that healthcare spending will reach USD 26 Billion by 2028, while the UAE aims to invest AED 118 Billion in the healthcare sector by 2027. Enhanced diagnostic infrastructure and medical technology adoption are facilitating the integration of aptamer-based assays. Healthcare facilities are prioritizing fast and accurate molecular tools, where aptamers are showing strong potential. This infrastructure growth is creating new opportunities for aptamer research and commercialization across the region.

COMPETITIVE LANDSCAPE:

The competitive landscape of the aptamers market is marked by the presence of several key players, including companies such as SomaLogic, Aptagen LLC, and Aptamer Group. These companies are focusing on innovation, with a strong emphasis on developing new aptamer-based products and expanding their applications in diagnostics and therapeutics. Competitive strategies include forming partnerships, conducting extensive R&D, and expanding their product portfolios. Additionally, there is a growing focus on enhancing the stability, specificity, and cost-effectiveness of aptamers to address a wide range of medical and research needs. The increasing demand for personalized medicine and targeted therapies further intensifies competition, with players striving to capture a larger share of this evolving market.

The report provides a comprehensive analysis of the competitive landscape in the aptamers market with detailed profiles of all major companies, including:

• Aptagen LLC
• Aptamer Group
• Aptamer Sciences Inc.
• Aptus Biotech S.L.
• Base Pair Biotechnologies Inc.
• IBA GmbH
• Kaneka Eurogentec S.A. (Kaneka Corporation)
• NeoVentures Biotechnology Inc.
• NOXXON Pharma
• SomaLogic Inc.
• TriLink BioTechnologies LLC
• Vivonics Inc.

Key Questions Answered in This Report

• 1.How big is the aptamers market?
• 2.What is the future outlook of the aptamers market?
• 3.What are the key factors driving the aptamers market?
• 4.Which region accounts for the largest aptamers market share?
• 5.Which are the leading companies in the global aptamers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Aptamers Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Nucleic Acid
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Peptide
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Diagnostics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Therapeutics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Research and Developments
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Aptagen LLC
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 Aptamer Group
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Aptamer Sciences Inc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Aptus Biotech S.L.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
  • 13.3.5 Base Pair Biotechnologies Inc.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 IBA GmbH
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
  • 13.3.7 Kaneka Eurogentec S.A. (Kaneka Corporation)
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 NeoVentures Biotechnology Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 NOXXON Pharma
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
  • 13.3.10 SomaLogic Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
  • 13.3.11 TriLink BioTechnologies LLC
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
  • 13.3.12 Vivonics Inc.
    • 13.3.12.1 Company Overview
    • 13.3.12.2 Product Portfolio